Biologic therapy of inflammatory bowel disease

Gastroenterology

Volumn 122, Issue 6, 2002, Pages 1592-1608

  Sandborn, William J ^a   Targan, Stephan R ^b  

^a MAYO CLINIC   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ALPHA INTERFERON; ALPHA4 INTEGRIN; ANTISENSE OLIGONUCLEOTIDE; BETA1A INTERFERON; EPIDERMAL GROWTH FACTOR; ETANERCEPT; GAMMA INTERFERON ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 2 RECEPTOR ANTIBODY; KERATINOCYTE GROWTH FACTOR; NATALIZUMAB; OKT 4; REPIFERMIN; SEMAPIMOD; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR BINDING PROTEIN; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CROHN DISEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; HUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS;

EID: 0036093570     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.33426     Document Type: Article

References (144)

1. Th1/Th2 cells
2. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
3. T regulatory cells 1 inhibit a Th2-specific response in vivo
4. Lymphocyte homing and homeostasis
5. Tumor necrosis factor: Biology and therapeutic inhibitors
6. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases
7. Inflammatory bowel disease: Etiology and pathogenesis
8. Recent developments in the immunology of inflammatory bowel disease
9. Role of cytokines in the pathogenesis of inflammatory bowel disease
10. Tumour necrosis factor and Crohn's disease
11. Role of NF-kappaB in immune and inflammatory responses in the gut
12. Interleukin-10 in the intestine
13. Biologic therapy for inflammatory bowel disease
14. Therapeutic monoclonal antibodies
15. Antisense-oligonucleotide therapy
16. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
17. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
18. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
19. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
20. Tumour-necrosis-factor antibody treatment in Crohn's disease
21. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
22. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease
23. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
24. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease study
25. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
26. Treatment of Crohn's disease (CD): Response to Remicade (infliximab) in the ACCENT I trial through week 54
27. Three dose induction regimen of infliximab (Remicade is superior to a single dose in patients with Crohn's disease (CD)
28. Infliximab for the treatment of fistulas in patients with Crohn's disease
29. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients
30. Infliximab in Crohn's disease: First anniversary clinical experience
31. Infliximab (Remicade) treatment allows Crohn's disease to reduce or discontinue concomitant corticosteroid use
32. Successful management of Crohn's disease of the ileoanal pouch with infliximab
33. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
34. Infliximab for refractory ulcerative colitis
35. Remicade (infliximab). Prescribing information
36. Human anti-chimeric antibody levels correlate with lack of response and infusion reactions following infliximab therapy
37. HACA formation after infliximab (Remicade) treatment in Crohn's disease is clearly associated with infusion reactions
38. A randomized, double-blind, placebo-controlled trial of intravenous hydrocortisone in reducing human anti-chimeric antibody following infliximab therapy
39. Delayed hypersensitivity to infliximab (Remicade) re-infusion after a 2-4 year interval without treatment
40. Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation
41. The relationship between infliximab treatment and lymphoma in Crohn's disease
42. Malignancy following Remicade therapy: Incidence and characteristics
43. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
44. Invasive pulmonary aspergillosis associated with infliximab therapy
45. Council of the Infectious Disease Society of America, September 1999
46. Targeted tuberculin testing and treatment of latent tuberculosis infection
47. Outcome of pregnancy in women receiving Remicade (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis
48. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
49. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
50. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease
51. Treatment of ulcerative colitis with an engineered human antiTNFα antibody CDP571
52. Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot trial
53. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
54. Recombinant soluble p55 receptor induces remission, is non-immunogenic and well tolerated in active Crohn's disease: Results of a randomized pilot trial
55. Inhibition of p38 MAP kinase as a therapeutic strategy
56. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated diseases
57. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
58. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
59. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
60. Characterization of the cell surface heterodimer VLA-4 and related peptides
61. Topographic distribution of homing receptors on B and T cells in human gut-associated lymphoid tissue: Relation of L-selectin and integrin alpha 4 beta 7 to naive and memory phenotypes
62. Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis
63. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody
64. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease
65. A randomised, double-blind, placebo-controlled, pan-European study of a recombinant humanised antibody to alpha 4 integrin (Antegren) in moderate to severely active Crohn's disease
66. Treatment of active ulcerative colitis with a recombinant humanised antibody to alpha4 integrin (Angegren)
67. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7
68. An ascending dose trial of humanized A4B7 antibody in ulcerative colitis (UC)
69. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
70. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
71. A randomized, placebo-controlled trial of antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels
72. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis
73. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses
74. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response
75. Antibodies to interleukin 12 abrogate established experimental colitis in mice
76. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
77. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice
78. The interferons. Mechanisms of action and clinical applications
79. Immunological and clinical effects of interferongamma on Crohn's disease
80. Low dose interferon gamma for refractory Crohn's disease
81. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones
82. Interleukin10-deficient mice develop chronic enterocolitis
83. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation
84. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
85. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
86. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease
87. Human recombinant interleukin-10 is safe and well tolerated but does not induce remission in steroid dependent Crohn's disease
88. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease
89. Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis
90. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
91. Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40CD40 ligand interactions for a sustained increase in mucosal IL-12
92. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu
93. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells
94. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production
95. Characterization of the in vitro and in vivo activity of monoclonal antibodies to human IL-18
96. The use of humanized, anti interleukin-2 receptor antibodies (Zenapax, Roche) in refractory ulcerative colitis
97. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
98. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
99. NF-κB signaling proteins as therapeutic targets for inflammatory bowel diseases
100. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
101. The immune system. Second of two parts
102. ICOS co-stimulatory receptor is essential for T-cell activation and function
103. ICOS is critical for CD40-mediated antibody class switching
104. ICOS is essential for effective T-helper-cell responses
105. T-cell co-stimulation through B7RP-1 and ICOS
106. T-cell co-stimulatory molecules are up-regulated on intestinal macrophages from inflammatory bowel disease mucosa
107. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand
108. Intestinal lymphocyte subpopulations in inflammatory bowel disease: An analysis by immunohistological and cell isolation techniques
109. Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and in inflammatory bowel disease
110. Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease
111. Remission of Crohn's disease after human immunodeficiency virus infection
112. Chimeric monoclonal anti-CD4 antibody therapy proves effective for treating inflammatory bowel disease
113. CD4-antibody treatment of inflammatory bowel disease: One-year follow up
114. CD4 antibody treatment in patients with active Crohn's disease: A phase 1 dose finding study
115. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody
116. Treatment of inflammatory bowel diesease with anti-CD4 monoclonal antibody
117. Anti-CD4-antibody treatment in inflammatory bowel disease without a long CD4+cell depletion
118. Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody
119. Growth factors in inflammatory bowel disease
120. Epidermal growth factor enemas are effective in the treatment of left-sided ulcerative colitis
121. Keratinocyte growth factor: A unique player in epithelial repair processes
122. Recombinant human keratinocyte growth factor (rHuKGF) ameliorates disease symptoms in both the DSS and CD45RB Hi cell transfer murine models of inflammatory bowel disease (IBD)
123. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis
124. Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats
125. Cellular responses to interferons and other cytokines: The JAK-STAT paradigm
126. Interferon treatment in mild to moderate active Crohn's disease: Preliminary results of an open label pilot study
127. Interferon alpha-2A (roferon) as a treatment of inflammatory bowel disease in children and adolescents
128. Induction of remission by interferonalpha in patients with chronic active ulcerative colitis
129. An open-labeled, randomized study comparing systemic interferon-alpha- 2A and prednisolone enemas in the treatment of left-sided ulcerative colitis
130. Alpha-interferon therapy in Crohn's disease: Initial clinical results
131. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease
132. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease
133. Treatment of Crohn's disease with interferon. A preliminary clinical trial
134. Recombinant human interferon-beta (INFB-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC)
135. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease
136. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease
137. Immunostimulation in Crohn's disease: Results of a pilot study of G-CSF (R-Methug-CSF) in mucosal and fistulizing Crohn's disease
138. Immune stimulation in Crohn's disease: Safety and efficacy of rhuGM-CSF for the treatment of active Crohn's disease
139. A preliminary study of growth hormone therapy for Crohn's disease
140. Interleukin-11: Review of molecular, cell biology, and clinical use
141. IL-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology
142. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats
143. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
144. Randomized, controlled trial of recombinant human interleukin 11 in patients with active Crohn's disease